Time- and dose-based gene expression profiles produced by a bile-duct-damaging chemical, 4,4'-methylene dianiline, in mouse liver in an acute phase.
A toxicogenomics study was performed in the mouse liver after treatment of a bile-duct-damaging chemical, 4,4'-methylene dianiline (MDA), across multiple doses and sampling times in an acute phase using the AB Expression Array System. Imprinting control region (ICR) mice were given a single oral administration of a low (10 mg/kg b.w.) or high (100 mg/kg b.w.) dose of MDA. Mice were sacrificed six, twenty-four, and seventy-two hours after treatment for serum chemistry, histopathology, and mRNA preparation from liver samples. Treatment with MDA increased liver-toxicity-related enzymes in blood and induced bile-duct cell injury, followed by regeneration. To explore potential biomarker gene profiles, the altered genes were categorized into four expression patterns depending on dose and time. Numerous functionally defined and unclassified genes in each category were up- or down-regulated throughout the period from cellular injury to the recovery phase, verified by RT-PCR. Many genes associated with liver toxicity and diseases belonged to one of these categories. The chemokine-mediated Th1 pathway was implicated in the inflammatory process. The genes associated with oxidative stress, apoptosis, and cell-cycle regulation were also dynamically responsive to MDA treatment. The Wnt/beta-catenin signaling pathway was likely responsible for the reconstitution process of the MDA-injured liver.
Kwon
Sun-Bom
SB
1 School of Veterinary Medicine and Institute of Veterinary Science, Kangwon National University, Chuncheon 200-701, Republic of Korea.
Park
Joon-Suk
JS
Yi
Jung-Yeon
JY
Hwang
Jae-Wong
JW
Kim
Mingoo
M
Lee
Mi-Ock
MO
Lee
Byung-Hoon
BH
Kim
Hyung-Lae
HL
Kim
Ju Han
JH
Chung
Heekyoung
H
Kong
Gu
G
Kang
Kyung-Sun
KS
Yoon
Byung-Il
BI
D000210:Acute-Phase Reaction / Q000209:etiology; D000410:Alanine Transaminase / Q000097:blood; D000814:Aniline Compounds / Q000633:toxicity*; D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001219:Aspartate Aminotransferases / Q000097:blood; D001652:Bile Ducts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001663:Bilirubin / Q000378:metabolism; D002273:Carcinogens / Q000633:toxicity*; D002453:Cell Cycle / Q000235:genetics / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D020869:Gene Expression Profiling; D018816:Genes, cdc; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008111:Liver Function Tests; D051379:Mice; D008813:Mice, Inbred ICR; D008954:Models, Biological; D018384:Oxidative Stress / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D013047:Specific Pathogen-Free Organisms; D018417:Th1 Cells / Q000378:metabolism; D013997:Time Factors; D043922:Toxicogenetics / Q000379:methods; D001559:Benzhydryl Compounds
D000410:Alanine Transaminase; D000814:Aniline Compounds; D001219:Aspartate Aminotransferases; D001663:Bilirubin; D002273:Carcinogens; D012333:RNA, Messenger; C009505:4,4'-diaminodiphenylmethane; D001559:Benzhydryl Compounds